HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced a total of 19 ZEVALIN related data presentations (5 oral, 14 posters) at the 53rd Annual Meeting of the American Society of Hematology (ASH), being held in San Diego, California, from December 10-13, 2011.
